Skip to main content

BNTX

Stock
Health Care
Biotechnology

Performance overview

BNTX Price
Price Chart

Forward-looking statistics

Beta
0.63
Risk
47.53%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/

Company info

SectorHealth Care
IndustryBiotechnology
Employees5K
Market cap$24.2B

Fundamentals

Enterprise value$13.9B
Revenue$3.2B
Revenue per employee
Profit margin-27.89%
Debt to equity1.55

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$3.76
Dividend per share
Revenue per share$11.43
Avg trading volume (30 day)$113M
Avg trading volume (10 day)$65M
Put-call ratio

Macro factor sensitivity

Growth+0.4
Credit+0.8
Liquidity+1.8
Inflation-6.6
Commodities+1.3
Interest Rates+3.4

Valuation

Dividend yield0.00%
PEG Ratio-28.21
Price to sales9.63
P/E Ratio-28.21
Enterprise Value to Revenue4.29
Price to book1.40

Upcoming events

Next earnings dayAugust 5, 2024
Next dividend day
Ex. dividend dayJune 2, 2022

News

5 Stocks To Ride The German Market Rally

Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the developed world in 2025.

Benzinga (June 16, 2025)
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trusted regulatory process and could sow public distrust in vaccinations and federal health agencies.

CNBC (June 10, 2025)
Bristol Myers Collaborates With BNTX for Oncology Candidate

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.

Zacks Investment Research (June 3, 2025)
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer

Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.

CNBC Television (June 2, 2025)
FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled

A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.

Forbes (February 27, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free